CRON

Cronos Group Inc. is a healthcare company operating in the drug manufacturers - specialty & generic industry. With a market capitalization of $1.03 billion and revenue of $132.36 million, it has a significant presence in its sector. The company's financial health is characterized by profitability margins: gross margin at 38.8%, operating margin at -13.8%, and profit margin at 27.3%. Returns on equity stand at 3.7% while returns on assets are negative at -1.4%. On the balance sheet, Cronos Group has a cash reserve of $824.17 million and debt of $1.74 million, with a debt-to-equity ratio of 0.15. Valuation metrics for Cronos Group include a P/E ratio of 24.55 (TTM) and -67.50 (forward), price to book at 0.96, and price to sales at 7.81. Revenue growth has been steady at 6.1% year-over-year while earnings growth has increased by 238.8%.